,,ii  #aahth ,,congress  #ast ,session  
,s4 #cf  ,,in ,,the ,,senate ,,of ,,the 
,,united ,,states  ,january #bd         
7legislative day1 ,january #c71         
#bjbc,mr4 ,rubio 7for himself and ,mr4  
,coons7 introduced the following bill2  
which was read twice and referred to the
 ,committee on ,health1 ,education1     
,labor1 and ,pensions  ,a ,,bill  ,to   
review domestic biopharmaceutical       
manufacturing capabilities in order to  
improve public health and medical       
preparedness and response capabilities  
and domestic biopharmaceutical          
manufacturing capabilities4  #a4 ,short 
title ,this ,act may be cited as the    
,agility in ,manufacturing ,preparedness
 ,act of #bjbc4  #b4 ,review of domestic
 biopharmaceutical manufacturing        
capabilities  7a7 ,in general ,the      
,secretary of ,health and ,human        
,services 7referred to in this section  
as the ,secretary71 in cooperation with 
the ,director of the ,biomedical        
,advanced ,research and ,development    

,authority1 shall seek to enter into an 
agreement with the ,national ,institute 
for ,innovation in ,manufacturing       
,biopharmaceuticals to perform the      
services described in subsection 7b74   
7b7 ,review and recommendations ,under  
an agreement described in subsection 7a7
 between the ,secretary1 the ,director  
of the ,biomedical ,advanced ,research  
and ,development ,authority1 and the    
,national ,institute for ,innovation in 
,manufacturing ,biopharmaceuticals1 the 
,national ,institute for ,innovation in 
,manufacturing ,biopharmaceuticals      
shall-- 7#a7 review current domestic    
biopharmaceutical manufacturing capacity
 at the ,department of ,health and      
,human ,services and such department's  
adaptability to various threats2  7#b7  
draft recommendations for developing1   
demonstrating1 deploying1 and advancing 
new domestic biopharmaceutical          
manufacturing technologies that address 
gaps identified under paragraph 7#a7 and
 align ,federal technologies with       

technologies available to the private   
sector1 including through the new       
,bio,m,a,p initiative of the ,biomedical
 ,advanced ,research and ,development   
,authority2 and  7#c7 identify other    
opportunities and priorities to improve 
the ,united ,states public health and   
medical preparedness and response       
capabilities and domestic               
biopharmaceutical manufacturing         
capabilities4